Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal hydromorphone vs TAP block for postoperative pain after abdominal surgery
ChiCTR2600128746Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Longquanyi District, Chengdu
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydromorphone in gastric cancer (GC), intestinal cancer, hepatic neoplasm and 4 more (2 arms), sponsored by The First People's Hospital of Longquanyi District, Chengdu. Primary endpoint: Cumulative pain intensity during mobilization within the first 24 h postoperatively. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
hydromorphone
03
Conditions
gastric cancer (GC)intestinal cancerhepatic neoplasmhepatolithiasis (HL)Fibromyoma (LM)
Beyond the preview
Go deeper on ChiCTR2600128746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128746.